[go: up one dir, main page]

MX2011011190A - Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas. - Google Patents

Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas.

Info

Publication number
MX2011011190A
MX2011011190A MX2011011190A MX2011011190A MX2011011190A MX 2011011190 A MX2011011190 A MX 2011011190A MX 2011011190 A MX2011011190 A MX 2011011190A MX 2011011190 A MX2011011190 A MX 2011011190A MX 2011011190 A MX2011011190 A MX 2011011190A
Authority
MX
Mexico
Prior art keywords
methods
treating
bacterial infection
quinolones
fluoro
Prior art date
Application number
MX2011011190A
Other languages
English (en)
Other versions
MX339077B (es
Inventor
Mike Dudley
David Griffith
Olga Rodny
Original Assignee
Mpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43011488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mpex Pharmaceuticals Inc filed Critical Mpex Pharmaceuticals Inc
Publication of MX2011011190A publication Critical patent/MX2011011190A/es
Publication of MX339077B publication Critical patent/MX339077B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen en la presente métodos para tratar una infección bacteriana pulmonar que comprende el desarrollo de bacterias bajo condiciones anaeróbicas utilizando un antibiótico de fluoroquinolona. El antibiótico de fluoroquinolona puede por ejemplo, ser levofloxacina o ofloxacina. También se describen métodos para inhibir el desarrollo de bacterias bajo condiciones anaeróbicas al exponer las bacterias a una cantidad de antibiótico de fluoroquinolona efectiva para inhibir el desarrollo de dichas bacterias.
MX2011011190A 2009-04-24 2010-04-22 Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas. MX339077B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17262509P 2009-04-24 2009-04-24
PCT/US2010/032128 WO2010124141A1 (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones

Publications (2)

Publication Number Publication Date
MX2011011190A true MX2011011190A (es) 2012-02-13
MX339077B MX339077B (es) 2016-05-10

Family

ID=43011488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011190A MX339077B (es) 2009-04-24 2010-04-22 Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas.

Country Status (28)

Country Link
US (2) US20120035166A1 (es)
EP (1) EP2421539B1 (es)
JP (2) JP6179844B2 (es)
KR (1) KR20120034626A (es)
CN (2) CN107050032A (es)
AU (1) AU2010238765B2 (es)
BR (1) BRPI1006626B8 (es)
CA (1) CA2759874C (es)
CL (1) CL2011002649A1 (es)
CO (1) CO6450642A2 (es)
CY (1) CY1122525T1 (es)
DK (1) DK2421539T3 (es)
ES (1) ES2755754T3 (es)
HR (1) HRP20191951T1 (es)
HU (1) HUE046595T2 (es)
IL (1) IL215777A (es)
LT (1) LT2421539T (es)
MX (1) MX339077B (es)
MY (1) MY178871A (es)
NZ (1) NZ596245A (es)
PL (1) PL2421539T3 (es)
PT (1) PT2421539T (es)
RU (1) RU2535056C2 (es)
SG (3) SG10201811494SA (es)
SI (1) SI2421539T1 (es)
SM (1) SMT201900645T1 (es)
WO (1) WO2010124141A1 (es)
ZA (1) ZA201107903B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN102202649A (zh) 2008-10-07 2011-09-28 Mpex医药有限公司 用于改进的药物动力学的氟喹诺酮气雾剂制剂
PL2346509T3 (pl) 2008-10-07 2021-03-08 Horizon Orphan Llc Lewofloksacyna w postaci aerozolu dla zmniejszania stanu zapalnego płuc
KR20120100904A (ko) 2009-09-04 2012-09-12 엠펙스 파마슈티컬즈, 인코포레이티드 낭포성 섬유증을 치료하기 위한 에어로졸화된 레보플록사신의 용도
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
EP2968801B1 (en) * 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6966835B2 (ja) * 2016-02-05 2021-11-17 ホライズン オーファン リミテッド ライアビリティ カンパニー 嚢胞性線維症のためのフルオロキノロン製剤
CN108849939B (zh) * 2018-07-31 2021-02-19 广东省农业科学院植物保护研究所 盐酸左氧氟沙星在制备用于防治烟草青枯病的农药制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230600B2 (en) 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
RU2255757C1 (ru) * 2004-06-22 2005-07-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Пептидное соединение, восстанавливающее функцию органов дыхания
EP1901749B1 (en) * 2005-05-18 2016-08-03 Raptor Pharmaceuticals Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2724009C (en) * 2008-05-15 2016-10-11 Novartis Ag Pulmonary delivery of a fluoroquinolone
CN102202649A (zh) * 2008-10-07 2011-09-28 Mpex医药有限公司 用于改进的药物动力学的氟喹诺酮气雾剂制剂

Also Published As

Publication number Publication date
EP2421539A1 (en) 2012-02-29
ZA201107903B (en) 2013-01-30
RU2535056C2 (ru) 2014-12-10
EP2421539A4 (en) 2014-01-29
BRPI1006626B8 (pt) 2021-05-25
PT2421539T (pt) 2019-11-22
ES2755754T3 (es) 2020-04-23
MY178871A (en) 2020-10-21
SMT201900645T1 (it) 2020-01-14
SG175288A1 (en) 2011-11-28
KR20120034626A (ko) 2012-04-12
CA2759874C (en) 2016-11-08
US20210015811A1 (en) 2021-01-21
HUE046595T2 (hu) 2020-03-30
JP2016053041A (ja) 2016-04-14
AU2010238765B2 (en) 2014-12-18
CN102427815A (zh) 2012-04-25
BRPI1006626A2 (pt) 2020-07-28
AU2010238765A1 (en) 2011-11-10
IL215777A (en) 2017-09-28
HRP20191951T1 (hr) 2021-05-14
IL215777A0 (en) 2012-01-31
SI2421539T1 (sl) 2019-12-31
CN107050032A (zh) 2017-08-18
CY1122525T1 (el) 2021-01-27
SG10201811494SA (en) 2019-01-30
MX339077B (es) 2016-05-10
RU2011145430A (ru) 2013-05-27
CO6450642A2 (es) 2012-05-31
JP6228580B2 (ja) 2017-11-08
CA2759874A1 (en) 2010-10-28
BRPI1006626B1 (pt) 2021-05-11
PL2421539T3 (pl) 2020-02-28
JP2012524811A (ja) 2012-10-18
DK2421539T3 (da) 2019-11-18
LT2421539T (lt) 2019-12-10
US20120035166A1 (en) 2012-02-09
CL2011002649A1 (es) 2012-06-22
JP6179844B2 (ja) 2017-08-16
NZ596245A (en) 2013-11-29
WO2010124141A1 (en) 2010-10-28
EP2421539B1 (en) 2019-10-23
SG10201403512TA (en) 2014-08-28

Similar Documents

Publication Publication Date Title
MY178871A (en) Methods of treating a pulmonary bacterial infection using fluoro-quinolones
MY174523A (en) ?-lactamase inhibitor and process for preparing the same
EP3409666A3 (en) Seca inhibitors and methods of making and using thereof
WO2012135016A3 (en) Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
NZ593111A (en) Antibacterial compounds
WO2018208985A3 (en) Antibacterial compounds
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
MX366793B (es) Metodos para preparar oxazolidinonas y composiciones que las contienen.
NZ708928A (en) Mannose derivatives for treating bacterial infections
EP2408294A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF WASTEWATER BY BREEDING PHOTOTAKTIC HETEROTROPHIC MICROORGANISMS
SG178952A1 (en) Chemical compounds
CA2710814C (en) Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
MX2013008162A (es) Inhibidores de pirimidina y topoisomerasa iv.
WO2012103295A3 (en) Small molecule rnase inhibitors and methods of use
IL287931A (en) Bioreactors for the growth of microorganisms
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
IN2012DN03846A (es)
IL284678A (en) Bioreactors for growing micro-organisms
PH12013501293A1 (en) Use of nitrogen-free peroxygen-releasing compound to reduce growth of contaminant microorganisms in ethanol fermentation
EA201170121A1 (ru) Лечение инфекций, вызванных антибиотикоустойчивыми бактериями
NZ713357A (en) Antimicrobial compounds and methods of making and using the same
MY156304A (en) 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
WO2012085255A3 (en) Volatile organic compounds from bacterial antagonists for controlling microbial growth
WO2011076912A3 (en) Methods and compositions for biologically controlling microbial growth on clean room equipment

Legal Events

Date Code Title Description
FG Grant or registration